CN106309546A - Extract for treating diabetic nephropathy - Google Patents
Extract for treating diabetic nephropathy Download PDFInfo
- Publication number
- CN106309546A CN106309546A CN201510942960.4A CN201510942960A CN106309546A CN 106309546 A CN106309546 A CN 106309546A CN 201510942960 A CN201510942960 A CN 201510942960A CN 106309546 A CN106309546 A CN 106309546A
- Authority
- CN
- China
- Prior art keywords
- petroleum ether
- herba rosmarini
- rosmarini officinalis
- extraction
- compositions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000007342 Diabetic Nephropathies Diseases 0.000 title claims abstract description 22
- 208000033679 diabetic kidney disease Diseases 0.000 title claims abstract description 22
- 239000000284 extract Substances 0.000 title claims description 12
- 239000003208 petroleum Substances 0.000 claims abstract description 56
- QRYRORQUOLYVBU-VBKZILBWSA-N carnosic acid Chemical compound CC([C@@H]1CC2)(C)CCC[C@]1(C(O)=O)C1=C2C=C(C(C)C)C(O)=C1O QRYRORQUOLYVBU-VBKZILBWSA-N 0.000 claims abstract description 20
- 239000000203 mixture Substances 0.000 claims abstract description 20
- CEEMRWKKNNEQDT-UHFFFAOYSA-N Rosmanol Natural products CC(C)c1cc2C(OC(=O)C)C3OC(=O)C4(CCCC(C)(C)C34)c2c(OC(=O)C)c1OC(=O)C CEEMRWKKNNEQDT-UHFFFAOYSA-N 0.000 claims abstract description 14
- LCAZOMIGFDQMNC-FORWCCJISA-N rosmanol Chemical compound C1CCC(C)(C)[C@@H]2[C@H]3[C@@H](O)C(C=C(C(=C4O)O)C(C)C)=C4[C@]21C(=O)O3 LCAZOMIGFDQMNC-FORWCCJISA-N 0.000 claims abstract description 13
- MMFRMKXYTWBMOM-UHFFFAOYSA-N Carnosol Natural products CCc1cc2C3CC4C(C)(C)CCCC4(C(=O)O3)c2c(O)c1O MMFRMKXYTWBMOM-UHFFFAOYSA-N 0.000 claims abstract description 8
- 235000004654 carnosol Nutrition 0.000 claims abstract description 8
- XUSYGBPHQBWGAD-PJSUUKDQSA-N Carnosol Chemical compound CC([C@@H]1C2)(C)CCC[C@@]11C(=O)O[C@@H]2C2=C1C(O)=C(O)C(C(C)C)=C2 XUSYGBPHQBWGAD-PJSUUKDQSA-N 0.000 claims abstract description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 112
- 238000000605 extraction Methods 0.000 claims description 77
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 28
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 27
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 25
- 238000002360 preparation method Methods 0.000 claims description 16
- 210000002700 urine Anatomy 0.000 claims description 16
- 239000007788 liquid Substances 0.000 claims description 14
- 239000012567 medical material Substances 0.000 claims description 14
- 239000000243 solution Substances 0.000 claims description 14
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 12
- 206010012601 diabetes mellitus Diseases 0.000 claims description 11
- 102000009027 Albumins Human genes 0.000 claims description 10
- 108010088751 Albumins Proteins 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 10
- 239000002253 acid Substances 0.000 claims description 9
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 claims description 8
- 230000029142 excretion Effects 0.000 claims description 8
- 230000002485 urinary effect Effects 0.000 claims description 8
- 240000003186 Stachytarpheta cayennensis Species 0.000 claims description 7
- 235000009233 Stachytarpheta cayennensis Nutrition 0.000 claims description 7
- 208000017169 kidney disease Diseases 0.000 claims description 7
- 150000004702 methyl esters Chemical class 0.000 claims description 6
- PRYXPGFZVGZNBL-ADLFWFRXSA-N salviol Chemical compound CC(C)c1cc2CC[C@H]3C(C)(C)C[C@H](O)C[C@]3(C)c2cc1O PRYXPGFZVGZNBL-ADLFWFRXSA-N 0.000 claims description 6
- AJSGWTLZEUBGFV-UHFFFAOYSA-N salviol Natural products CC(C)c1cc2CCC3C(CC(O)CC3(C)C)c2cc1O AJSGWTLZEUBGFV-UHFFFAOYSA-N 0.000 claims description 6
- 238000001819 mass spectrum Methods 0.000 claims description 5
- 239000007864 aqueous solution Substances 0.000 claims description 4
- 229960003624 creatine Drugs 0.000 claims description 4
- 239000006046 creatine Substances 0.000 claims description 4
- 238000002481 ethanol extraction Methods 0.000 claims description 4
- 239000000469 ethanolic extract Substances 0.000 claims description 4
- 235000013305 food Nutrition 0.000 claims description 4
- 239000000401 methanolic extract Substances 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 102000004169 proteins and genes Human genes 0.000 claims description 4
- 108090000623 proteins and genes Proteins 0.000 claims description 4
- 238000003808 methanol extraction Methods 0.000 claims description 3
- HVPRQCPIJRYXQV-UHFFFAOYSA-N phenanthren-2-ylmethanol Chemical compound C1=CC=C2C3=CC=C(CO)C=C3C=CC2=C1 HVPRQCPIJRYXQV-UHFFFAOYSA-N 0.000 claims description 3
- KFDKNTQGTAEZGC-UHFFFAOYSA-N phenanthrene-1-carboxylic acid Chemical compound C1=CC2=CC=CC=C2C2=C1C(C(=O)O)=CC=C2 KFDKNTQGTAEZGC-UHFFFAOYSA-N 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 238000003745 diagnosis Methods 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 238000004090 dissolution Methods 0.000 claims description 2
- 235000013376 functional food Nutrition 0.000 claims description 2
- 230000036541 health Effects 0.000 claims description 2
- 239000000314 lubricant Substances 0.000 claims description 2
- 241001529742 Rosmarinus Species 0.000 abstract description 4
- 239000012259 ether extract Substances 0.000 abstract description 3
- LCAZOMIGFDQMNC-UHFFFAOYSA-N Epirosmanol Chemical compound C1CCC(C)(C)C2C3C(O)C(C=C(C(=C4O)O)C(C)C)=C4C21C(=O)O3 LCAZOMIGFDQMNC-UHFFFAOYSA-N 0.000 abstract 1
- -1 carnosol methyl ester Chemical class 0.000 abstract 1
- UXVPWKDITRJELA-WWNBULGVSA-N epiisorosmanol Chemical compound C1CCC(C)(C)[C@@H]2[C@H](O)[C@H]3C(C=C(C(=C4O)O)C(C)C)=C4[C@]21C(=O)O3 UXVPWKDITRJELA-WWNBULGVSA-N 0.000 abstract 1
- YYSJWXBVPBLJHZ-CIWZLLHZSA-N epirosmanol Natural products CC(C)c1cc2[C@@H](O)[C@H]3OC(=O)[C@@]4(C[C@@H](O)CC(C)(C)[C@H]34)c2c(O)c1O YYSJWXBVPBLJHZ-CIWZLLHZSA-N 0.000 abstract 1
- QCBIICHRPQFAOD-UHFFFAOYSA-N isorosmanol Natural products CC(C)c1cc2C3OC(=O)C4(CCCC(C)(C)C4C3OC(=O)C)c2c(OC(=O)C)c1OC(=O)C QCBIICHRPQFAOD-UHFFFAOYSA-N 0.000 abstract 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical group O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 35
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 13
- 239000008103 glucose Substances 0.000 description 13
- 239000008280 blood Substances 0.000 description 12
- 210000004369 blood Anatomy 0.000 description 12
- 238000011740 C57BL/6 mouse Methods 0.000 description 11
- 241000699670 Mus sp. Species 0.000 description 11
- 241000699666 Mus <mouse, genus> Species 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 9
- 208000020832 chronic kidney disease Diseases 0.000 description 8
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 8
- 201000000523 end stage renal failure Diseases 0.000 description 8
- 229960001052 streptozocin Drugs 0.000 description 8
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 7
- 230000008859 change Effects 0.000 description 7
- 208000028208 end stage renal disease Diseases 0.000 description 6
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 230000014759 maintenance of location Effects 0.000 description 5
- 239000012071 phase Substances 0.000 description 5
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 229940109239 creatinine Drugs 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- DOUMFZQKYFQNTF-WUTVXBCWSA-N (R)-rosmarinic acid Chemical compound C([C@H](C(=O)O)OC(=O)\C=C\C=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 DOUMFZQKYFQNTF-WUTVXBCWSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 206010018473 Glycosuria Diseases 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 244000295490 Salvia japonica Species 0.000 description 2
- 235000005794 Salvia japonica Nutrition 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 210000002318 cardia Anatomy 0.000 description 2
- 238000012937 correction Methods 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000003651 drinking water Substances 0.000 description 2
- 235000020188 drinking water Nutrition 0.000 description 2
- 201000006549 dyspepsia Diseases 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 235000013312 flour Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 206010025482 malaise Diseases 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 235000020925 non fasting Nutrition 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 235000010265 sodium sulphite Nutrition 0.000 description 2
- 239000007901 soft capsule Substances 0.000 description 2
- 239000004575 stone Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 2
- WCGUUGGRBIKTOS-GPOJBZKASA-N (3beta)-3-hydroxyurs-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C WCGUUGGRBIKTOS-GPOJBZKASA-N 0.000 description 1
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 206010001580 Albuminuria Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 239000002947 C09CA04 - Irbesartan Substances 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 208000012239 Developmental disease Diseases 0.000 description 1
- 206010054044 Diabetic microangiopathy Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 241000207923 Lamiaceae Species 0.000 description 1
- 206010024264 Lethargy Diseases 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- ZZAFFYPNLYCDEP-HNNXBMFYSA-N Rosmarinsaeure Natural products OC(=O)[C@H](Cc1cccc(O)c1O)OC(=O)C=Cc2ccc(O)c(O)c2 ZZAFFYPNLYCDEP-HNNXBMFYSA-N 0.000 description 1
- 244000178231 Rosmarinus officinalis Species 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 238000000889 atomisation Methods 0.000 description 1
- 238000005452 bending Methods 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 201000009101 diabetic angiopathy Diseases 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- WBZKQQHYRPRKNJ-UHFFFAOYSA-L disulfite Chemical compound [O-]S(=O)S([O-])(=O)=O WBZKQQHYRPRKNJ-UHFFFAOYSA-L 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000024924 glomerular filtration Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000037308 hair color Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- YCPOHTHPUREGFM-UHFFFAOYSA-N irbesartan Chemical compound O=C1N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C=2[N]N=NN=2)C(CCCC)=NC21CCCC2 YCPOHTHPUREGFM-UHFFFAOYSA-N 0.000 description 1
- 229960002198 irbesartan Drugs 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- DKXULEFCEORBJK-UHFFFAOYSA-N magnesium;octadecanoic acid Chemical compound [Mg].CCCCCCCCCCCCCCCCCC(O)=O DKXULEFCEORBJK-UHFFFAOYSA-N 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000012982 microporous membrane Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 201000001474 proteinuria Diseases 0.000 description 1
- 230000008327 renal blood flow Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- DOUMFZQKYFQNTF-MRXNPFEDSA-N rosemarinic acid Natural products C([C@H](C(=O)O)OC(=O)C=CC=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 DOUMFZQKYFQNTF-MRXNPFEDSA-N 0.000 description 1
- TVHVQJFBWRLYOD-UHFFFAOYSA-N rosmarinic acid Natural products OC(=O)C(Cc1ccc(O)c(O)c1)OC(=Cc2ccc(O)c(O)c2)C=O TVHVQJFBWRLYOD-UHFFFAOYSA-N 0.000 description 1
- 235000015639 rosmarinus officinalis Nutrition 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 229940083466 soybean lecithin Drugs 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 229940096998 ursolic acid Drugs 0.000 description 1
- PLSAJKYPRJGMHO-UHFFFAOYSA-N ursolic acid Natural products CC1CCC2(CCC3(C)C(C=CC4C5(C)CCC(O)C(C)(C)C5CCC34C)C2C1C)C(=O)O PLSAJKYPRJGMHO-UHFFFAOYSA-N 0.000 description 1
- 239000002550 vasoactive agent Substances 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/55—Liquid-liquid separation; Phase separation
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a rosemary petroleum ether extract for preparing a composition capable of treating or preventing diabetic nephropathy. The rosemary petroleum ether extract comprises the following components: carnosic acid, carnosol, rosmanol, epirosmanol, epiisorosmanol, carnosol methyl ester and the like.
Description
Technical field
The present invention relates to the new medical use of a Plant Extracts, Herba Rosmarini Officinalis extract is at preparation treatment glycosuria
Application in sick nephropathy medicine, belongs to natural medicine field.
Background technology
In recent years, along with social progress, the improvement of living and diet structure change, the sickness rate of diabetes is year by year
Increasing, the trend that becomes younger is aggravated.Diabetic nephropathy (Diabetic nephropathy, DN) is diabetes patient
One of most important complication, the most likely develops into end stagerenaldisease (the End stage renal of high fatality rate
Disease, ESRD).It is the second largest cause of disease of end stagerenaldisease at China DN, and in western countries, DN
Become the primary factor of end stagerenaldisease morbidity already.Diabetic nephropathy be the modal blood capillary of diabetes also
Send out one of disease, the main cause be also that diabetics is lethal, disabling.The metabolism complicated due to its existence is disorderly
Disorderly, once develop into End-stage renal disease, often more thorny than the treatment of other kidney diseases, therefore and
Time preventing and treating for delaying the significant of diabetic nephropathy.
Increasing along with DN sickness rate in recent years, also achieves bigger entering to its pathogenetic research
Exhibition.It is generally acknowledged and mainly answered by inherited genetic factors, the change of renal blood flow kinetics, biochemical metabolism disorder, oxidation
Swash the many reasons such as damage, hypertension, cell growth factor abnormal increase and vaso-active substance Developmental and Metabolic Disorder
Influence each other and jointly cause the generation of DN.
Diabetic occurs that kidney damage is considered as diabetic nephropathy clinically, family has kidney patient,
Substantially hypertension, insulin resistant, it is bright that glomerule rate filters (Glomerular filtration rate, GFR)
Aobvious too high or companion severe hypertension person is the high risk factor that diabetic nephropathy occurs.Diabetes clinical manifestation is main
It was divided into for 5 phases, is the loose high functional period of glomerule respectively, without clinical symptoms renal damage phase, diabetic nephropathy morning
Phase, albuminuria nephropathy phase, renal failure stage.
Clinical diabetes diagnosis of nephropathy is mainly diabetics continuous proteinuria ＞ 0.5g/24h, glycosuria in early days
The urine albumen amount of sick nephropathy is 0.15-0.5g/24h, and urinary albumin excretion ratio is 15-200 μ g/min.Diagnose more tired
Difficulty person, should damage situation in conjunction with the diabetic microangiopathy of other organs.Section carries out Renal biospy if desired.
Diabetic nephropathy does not has good targeted drug at present.Patient, mainly by controlling blood glucose, blood pressure, adjusts
Joint diet is with relief of symptoms.The patient entering end stage renal failure then needs to carry out dialysis and organ shifting
Plant, but this measure can not prevent diabetic nephropathy from occurring again.
Herba Rosmarini Officinalis (Rosmarinus officinalis L.) Labiatae shrub, originates in Mediterranean Region.China
Academy of science's Institute of Zoology successfully introduced Herba Rosmarini Officinalis from Spain in 1981, and composition is mainly Salvia japonica Thunb.
Acid, carnosol, rosmanol, ursolic acid, rosmarinic acid etc..Rosemary plant is evergreen shrubs, strain
Uprightly, stem high about 1 meter (sometimes up to 2 meters).Leaf narrow apicule shape, is about 1 centimetre, the pine of likeness in form bending
Pin；Bottle green, above light, below white, leaf margin to blade back crimp, blade dissipates pinaster fragrance.
Herba Rosmarini Officinalis has tranquillizing and allaying excitement, refreshment effect, and dyspepsia and stomachache are all had certain curative effect.Also may be used
For treating the multiple diseases such as insomnia, cardiopalmus, headache, dyspepsia.External can treat wound and joint
Scorching.Also there is strong heart, promote that metabolism, the blood circulation etc. of promotion peripheral vessel act on.The most also change
Obstacle in terms of kind language, vision, audition, strengthens attention, treats rheumatalgia, strengthens liver function,
Reduce blood glucose, contribute to the treatment of arteriosclerosis, help the extremity of paralysis to reactivate ability.In recent years,
Herba Rosmarini Officinalis has been in progress on treating diabetes, but Herba Rosmarini Officinalis ligroin extraction is in diabetic nephropathy side
The most do not had been reported that.
Summary of the invention
The invention discloses Herba Rosmarini Officinalis ligroin extraction answering in the compositions of preparation treatment diabetic nephropathy
With.
The invention discloses extract is dark green powder or cream solid.
The component that the invention discloses Herba Rosmarini Officinalis ligroin extraction is: carnosic acid, carnosol, fan are repeatedly
Fragrant phenol, table rosmanol, the different rosmanol of table, rat-tail acid methyl ester, Salviol, 1-
Phenanthrenecarboxylic acid、2-Phenanthrenemethanol。
The component that the invention discloses Herba Rosmarini Officinalis ligroin extraction is: rosmanol, carnosol, rat-tail
Oxalic acid, rat-tail acid methyl ester, Salviol.Its relative mass spectra peak area ratio is: 2.23: 10.12: 39.64:
2.93∶32.32.(retention time as shown in table 1., mass spectrum such as Fig. 1. shown)
The invention discloses the compositions for preparing preventing and treating diabetic nephropathy, containing of Herba Rosmarini Officinalis ligroin extraction
Weight range is 1mg-2g/mg.
The compositions that the invention discloses, it is prepared as: medicine, health product or functional food, excipient
Or carrier is excipient conventional in pharmacy or field of food or carrier, such as diluent, disintegrating agent, lubricant
Deng.
The invention discloses the compositions for preparing preventing and treating diabetic nephropathy, Herba Rosmarini Officinalis ligroin extraction
Preparation method is: alcohol extraction Herba Rosmarini Officinalis medical material, with water dissolution alcohol extraction thing, uses petroleum ether extraction aqueous solution,
Merge petroleum ether layer, reclaim petroleum ether and obtain Herba Rosmarini Officinalis ligroin extraction.
The invention discloses the compositions for preparing preventing and treating diabetic nephropathy, Herba Rosmarini Officinalis ligroin extraction
Preparation method is:
Herba Rosmarini Officinalis medical material ethanol extraction, merges 95% ethanol extract, reclaims ethanol, and extractum adds water and makes
Molten, add petroleum ether, petroleum ether and solution and extract repeatedly, merge petroleum ether layer, reclaim petroleum ether and must be confused repeatedly
Fragrant ligroin extraction.
Herba Rosmarini Officinalis medical material methanol extraction, merges methanol extract liquid, reclaims methanol, and extractum adds water and makes molten, adds
Enter petroleum ether, petroleum ether and solution according to extraction repeatedly, merge petroleum ether layer, reclaim petroleum ether and obtain Herba Rosmarini Officinalis
Ligroin extraction.
Herba Rosmarini Officinalis medical material n-butanol extraction, merges n-butanol extracting liquid, reclaims n-butyl alcohol, and extractum adds water and makes
Molten, add petroleum ether, petroleum ether and solution and extract repeatedly, merge petroleum ether layer, reclaim petroleum ether and must be confused repeatedly
Fragrant ligroin extraction.
The preparation method that the invention discloses Herba Rosmarini Officinalis ligroin extraction is: Herba Rosmarini Officinalis medical material 10 times amount
95% ethanol extraction 3 times, 1h/ time, merges 95% ethanol extract, reclaims ethanol, extractum add water make molten,
Adding petroleum ether, petroleum ether and solution are according to 1；1 extraction three times, merges petroleum ether layer, reclaims petroleum ether and obtains
Herba Rosmarini Officinalis ligroin extraction.
The preparation method that the invention discloses Herba Rosmarini Officinalis ligroin extraction is: Herba Rosmarini Officinalis medical material is by 10 times amount first
Alcohol extraction 3 times, 1h/ time, merge methanol extract liquid, reclaim methanol, extractum add water make molten, add oil
Ether, petroleum ether and solution are according to 1；1 extraction three times, merges petroleum ether layer, reclaims petroleum ether and obtains Herba Rosmarini Officinalis stone
Oil ether extract.
The preparation method that the invention discloses Herba Rosmarini Officinalis ligroin extraction is: Herba Rosmarini Officinalis medical material is by 10 times amount just
Butyl alcohol extraction 3 times, 1h/ time, merge n-butanol extracting liquid, reclaim n-butyl alcohol, extractum add water make molten, add
Petroleum ether, petroleum ether and solution are according to 1；1 extraction three times, merges petroleum ether layer, reclaims petroleum ether and must be confused repeatedly
Fragrant ligroin extraction.
Based on above-mentioned discovery, the present invention has completed related experiment.In order to make it easy to understand, below will be by attached
Figure and specific embodiment are described in detail.It is important to note that specific embodiments and the drawings be only for
Explanation, it is clear that those skilled in the art can according to illustrating herein, the present invention carried out various correction or
Change, within these corrections and change also will include the scope of the invention in.
Accompanying drawing explanation
Fig. 1. Herba Rosmarini Officinalis ligroin extraction HPLC-ESI-Q-TOF-MS total ion current figure
Fig. 2 .C57BL/6 group, STZ+Vehicle group, STZ+Irbesartan group and STZ+PFR group are little to DN
The impact of Mus blood glucose
Fig. 3 .C57BL/6 group, STZ+Vehicle group, STZ+Irbesartan group and STZ+PFR group are little to DN
The impact of Mus urinary albumin excretion ratio
Fig. 4 .C57BL/6 group, STZ+Vehicle group, STZ+Irbesartan group and STZ+PFR group are little to DN
The impact of Mus UAlb/UCr
Detailed description of the invention
Embodiment 1
Herba Rosmarini Officinalis ligroin extraction extraction process
Herba Rosmarini Officinalis medical material 10 times amount 95% ethanol extraction 3 times, 1h/ time, merges 95% ethanol extract, reclaims
Ethanol, extractum add water make molten, add petroleum ether, petroleum ether and solution are according to 1；1 extraction three times, merges stone
Oil ether layer, reclaims petroleum ether and obtains Herba Rosmarini Officinalis ligroin extraction.
Embodiment 2
Herba Rosmarini Officinalis ligroin extraction Components identification
95% ethanol dissolves Herba Rosmarini Officinalis ligroin extraction 10mg/ml, and 12,000rpm are centrifuged 10min,
Take supernatant and carry out liquid phase analysis,
Use Agilent 1290 UPLC-6520 QTOF MS,
Flowing is (A) 0.1% aqueous formic acid and (B) acetonitrile mutually.
Flowing phase elution program is:
10%B (0min),
30%B (5min),
50%B (10min),
80%B (15min),
100%B (25-30min).
Flow velocity is 0.8ml/min.
Mass spectrum is dried gas temperature 350 DEG C, is dried gas flow rate 10L/h, atomization air pressure 35psig, ESI
Ion source, electron spray voltage 3500v, crack voltage 120v, skimmer 65v, OCTIRF
Vgp750v, scanning ion range 100-1100. bis-grades collision voltage 20v；40v；70v.
Mass Spectrometric Identification result such as following table
Can determine that the component that the invention discloses Herba Rosmarini Officinalis ligroin extraction is: carnosic acid, Salvia japonica Thunb.
Phenol, rosmanol, table rosmanol, the different rosmanol of table, rat-tail acid methyl ester, Salviol, 1-
The compounds such as Phenanthrenecarboxylic acid, 2-Phenanthrenemethanol.
Table 1. Herba Rosmarini Officinalis ligroin extraction mass spectral characteristi
Rosmanol, carnosol, carnosic acid, rat-tail acid methyl ester, Salviol.Its mass spectrum is relative to face, peak
Long-pending ratio is: 2.23: 10.12: 39.64: 2.93: 32.32 (collection of illustrative plates such as Fig. 1. shown).
Embodiment 3
The extract therapeutical effect experimentation to C57BL/6 Experimental Diabetes of Mice nephropathy
This experiment English abbreviation used is as follows.
English abbreviation vocabulary
English abbreviation English full name Chinese full name
PFR Petroleum ether fraction of rosemary Herba Rosmarini Officinalis ligroin extraction
DN Diabetic nephropathy diabetic nephropathy
ESRD End-stage renal diseas end stagerenaldisease
FBG Fasting blood glucose fasting glucose
STZ Streptozocin streptozotocin
UAER Urinary albumin excretion rate urinary albumin excretion ratio
UAlb Urinary albumin microdose urine protein
UCr Urinary creatinine urine creatine
Experimental technique and the experimental result of the present invention are as follows
2.1 experiment material
2.1.1 laboratory animal
C57BL/6 mice, male, body weight 20 ± 2g, Yangzhou University's animal medicine experiment teaching center carry
Confession, the certification of fitness number: SCXK-(Soviet Union) 2012-0004.
2.1.2 medicine and reagent
Biological study institute is built up in microalbumin (m-Alb) testing cassete (ELISA method) Nanjing
Lot number: 20150526
Hereinafter Herba Rosmarini Officinalis ligroin extraction is referred to as PFR.
2.1.3 experimental apparatus
2.2 experimental technique
2.2.1 medicine preparation
Diet formulation: normal mouse feedstuff.
The preparation of streptozotocin (STZ) solution: STZ is in less than-20 DEG C preservations.Face the used time with citric acid
2.1g addition distilled water 100mL is made into A liquid.Sodium citrate 2.94g adds in distilled water 100mL and joins
Become B liquid.A, B liquid measures pH value by 1: 1.32 mixing, pH meter, regulates pH=4.2-4.5, is i.e.
Required sodium citrate buffer solution.Facing the used time becomes the chain urea of 3mg/ml to help STZ lemon acid sodium buffer
Rhzomorph solution, lucifuge, in 30min, injection is complete.
Medicine is prepared: PFR 0.5% sodium carboxymethyl cellulose (CMC-Na) is made into the molten of 7.72mg/ml
Liquid.Irbesartan is made into the solution of 0.75mg/ml with the CMC-Na of 0.5%.
2.2.2 the foundation of experimental model and medication
It is randomly divided into normal group (12) and model group (26 after 38 C57BL/6 mice adaptabilities are fed 7d
Only), feeding normal diet every day.After 7d, give model group continuous lumbar injection STZ (60mg/kg) 5d.2w
After, tail point takes blood, detects fasting glucose.List the mice of fasting blood sugar ＞ 16mmol/L in diabetes to move
Thing.
Successful for modeling diabetic mice is randomly divided into 3 groups by blood glucose and body weight, it may be assumed that STZ+Vehicle group
(10), STZ+PFR (154.4mg/kg) group (5), STZ+Irbesartan group (9).Alternative
12 normal group mices are as C57BL/6 group.Concrete dosage regimen is:
Each treated animal every day is according to such scheme gastric infusion, continuous 24w.Test the last week, collect urine
Liquid.Mice is put into 24h in metabolic cage, and non-fasting can't help water, collects 24h urine.Before experiment terminates
Water is can't help in 12h fasting, surveys fasting glucose by blood glucose meter.
2.3 observation index and collection of specimens
2.3.1 refer generally to target observe
Each the group general state of mice, fasting glucose, body weight in monitoring experimentation, ingest and water uptake etc.
Change.
2.3.2 the mensuration of urine protein
The last week is collected each group of mice 24h urine sample in experiment, stays non-fasting during urine, can't help water, is put by mice
Enter in clean metabolic cage, take 2ml, 5000rpm after record urine volume and be centrifuged 1min, remove sediment, subpackage
In EP pipe ,-80 DEG C of Refrigerator stores.Urine albumin concentration is detected by ELISA kit.
2.3.3 the mensuration of urine creatine
The last week is collected each group of mice 24h urine sample in experiment, with creatine concentration in test kit detection urine.
2.4 statistical method
Experimental data, t inspection between measurement data group, P ＜ 0.05 is for having significance statistics meaning
Justice.(* P ＜ 0.05, * * P ＜ 0.01, * * * P ＜ 0.001)
2.5 experimental result
2.5.1 general state is observed
After model group mouse peritoneal injection STZ 14d, general state shows themselves in that movable minimizing；Polydipsia is flat
Equal amount of drinking water is three times of C57BL/6 group；Polyuria, bedding and padding are the moistest, change 1-2 time the most day by day, body
Heavily being gradually reduced, lethargy, hair color is gloomy, coarse.Compare with STZ+Vehicle group, STZ+PFR
Group, the amount of drinking water of STZ+Irbesartan group mice, hydrouria, weight loss and the mental status etc. are the most
Improve.
2.5.2 PFR on impact
Comparing with C57BL/6 group, after 24 weeks, STZ+Vehicle group mouse blood sugar value significantly raises (P ＜
0.001).Comparing with STZ+Vehicle group, STZ+PFR group blood glucose value all significantly reduces (P ＜ 0.05),
STZ+Irbesartanl group blood glucose value not statistically significant (P ＞ 0.05).Experimental result is shown in Fig. 2..
C56BL/6 mice fasting glucose (mM) tested by table 2.
2.5.3 the PFR impact on DN mouse retention albumin excretion rate
Compare STZ+Vehicle group urinary albumin excretion ratio (UAER) with C57BL/6 group and significantly raise (P
＜ 0.001).Comparing with STZ+Vehicle group, STZ+PFR group UAER significantly reduces (P ＜ 0.01).
STZ+Irbesartanl group UAER not statistically significant (P ＞ 0.05) experimental result is shown in Fig. 3..
C56BL/6 mouse retention albumin excretion rate (μ g/24h) tested by table 3.
2.5.4 the PFR impact on DN mouse retention microalbumin Yu creatinine ratio
Compare with C57BL/6 group, STZ+Vehicle group microdose urine protein and creatinine ratio
(UAlb/UCr) significantly (P ＜ 0.001) is raised.Compare with STZ+Vehicle group, STZ+PFR group
UAlb/UCr value significantly reduces (P ＜ 0.01).STZ+Irbesartanl group UAlb/UCr value not statistically significant
(P ＞ 0.05) experimental result is shown in Fig. 4..
Table 4. tests C56BL/6 mouse retention microalbumin and creatinine ratio (μ g/mg)
Embodiment 4
The preparation of Herba Rosmarini Officinalis ligroin extraction
The tablet of Herba Rosmarini Officinalis ligroin extraction: Herba Rosmarini Officinalis ligroin extraction 10mg, starch 88g, stearic
Acid magnesium 3g
Preparation technology: the Herba Rosmarini Officinalis ligroin extraction of Example 1 crosses 100 mesh sieves, adds starch, tristearin
Acid magnesium mix homogeneously, makes granule, is dried, tabletting, to obtain final product.
The capsule of Herba Rosmarini Officinalis ligroin extraction
Herba Rosmarini Officinalis ligroin extraction 10mg, starch 88g, magnesium stearate 3g
Preparation technology: the Herba Rosmarini Officinalis ligroin extraction of Example 1 crosses 100 mesh sieves, adds starch, hard
Fatty acid magnesium mix homogeneously, makes granule, is dried, encapsulated, to obtain final product.
The soft capsule of Herba Rosmarini Officinalis ligroin extraction
Herba Rosmarini Officinalis ligroin extraction 10mg, soybean lecithin 100g
Preparation technology: the Herba Rosmarini Officinalis ligroin extraction of Example 1, adds the soft phospholipid of Semen sojae atricolor, and colloid mill mixes
Even, evacuation, compacting, obtain soft capsule.
The lyophilized powder of Herba Rosmarini Officinalis ligroin extraction:
Herba Rosmarini Officinalis ligroin extraction 2.0g, sodium sulfite 4.0g, ethanol 50ml, add water and be settled to
1000mL；
Preparation technology: fan's Herba Rosmarini Officinalis ligroin extraction of Example 1 disperses in ethanol, sodium sulfite
Soluble in water, will be gradually added into by metabisulfite solution under ultrasonic or stirring condition, make into clear molten
Liquid；Add water and be settled to enough；Through 0.22 μM of filtering with microporous membrane, lyophilization obtains.
Take Herba Rosmarini Officinalis extract 10 grams, add 1000ml propylene glycol and 1000ml water for injection, stir molten
Solve, filter, sterilizing, canned, every 2ml, obtain Herba Rosmarini Officinalis extract injection.
Embodiment 5
The food formulation of Herba Rosmarini Officinalis ligroin extraction
Dry yeast 5g, warm water 90ml, water are a little, flour 150g, Herba Rosmarini Officinalis ligroin extraction 5mg, plant
Thing oil 10g, Cardia Salt are a little
Cookies way: yeast is sprinkling upon in warm water to stir and dissolves, adds the Herba Rosmarini Officinalis petroleum ether of embodiment 1
Extract.Add flour stirring, add vegetable oil, be kneaded into smooth dough；It is thick that 0.2cm made by dough
Thin slice；Extruding moulding, sting hole, surface sprinkles water, sprinkles some Cardia Salts, and room temperature is fermented 10 minutes；
Baking box preheats 120 degree, is placed on upper strata, roasting about 10 minutes, must contain the food of Herba Rosmarini Officinalis ligroin extraction.
Embodiment 6
Herba Rosmarini Officinalis ligroin extraction extraction process
Herba Rosmarini Officinalis medical material 10 times amount methanol extraction 3 times, 1h/ time, merges methanol extract liquid, reclaims methanol,
Extractum add water make molten, add petroleum ether, petroleum ether and aqueous solution are according to 1；1 extraction three times, merges petroleum ether
Layer, reclaims petroleum ether and obtains Herba Rosmarini Officinalis ligroin extraction.
Embodiment 7
Herba Rosmarini Officinalis ligroin extraction extraction process
Herba Rosmarini Officinalis medical material 10 times amount n-butanol extraction 3 times, 1h/ time, merges n-butanol extracting liquid, is just reclaiming
Butanol, extractum add water make molten, add petroleum ether, petroleum ether and aqueous solution are according to 1；1 extraction three times, merges
Petroleum ether layer, reclaims petroleum ether and obtains Herba Rosmarini Officinalis ligroin extraction.
Claims (8)
1. Herba Rosmarini Officinalis ligroin extraction is for preparing treatment or the compositions of diabetes and nephropathy preventing.
2. according to the compositions in claim 1, it is characterized by: the component of Herba Rosmarini Officinalis ligroin extraction is: carnosic acid, carnosol, rosmanol, table rosmanol, the different rosmanol of table, rat-tail acid methyl ester, Salviol, 1-Phenanthrenecarboxylic acid, 2-Phenanthrenemethanol.
3. according to the compositions in claim 1, it is characterized by: the component of Herba Rosmarini Officinalis ligroin extraction is: rosmanol, carnosol, carnosic acid, rat-tail acid methyl ester, Salviol.Its relative mass spectra peak area ratio is: 2.23: 10.12: 39.64: 2.93: 32.32.
4., according to the compositions in claim 1, it is characterized by:
For preparing the compositions of preventing and treating diabetic nephropathy, the content range of Herba Rosmarini Officinalis ligroin extraction is 1mg-2g/kg.
5. according to the compositions in claim 1, it is characterized by: medicine, health product or functional food, excipient or carrier are excipient conventional in pharmacy or field of food or carrier, such as diluent, disintegrating agent, lubricant etc..
6., according to the compositions in claim 1, it is characterized by:
The preparation method of Herba Rosmarini Officinalis ligroin extraction is: alcohol extraction Herba Rosmarini Officinalis medical material, with water dissolution alcohol extraction thing, uses petroleum ether extraction aqueous solution, merges petroleum ether layer, reclaims petroleum ether and obtains Herba Rosmarini Officinalis ligroin extraction.
7., according to the compositions in claim 1, it is characterized by:
The preparation method of Herba Rosmarini Officinalis ligroin extraction is:
Herba Rosmarini Officinalis medical material ethanol extraction, merges 95% ethanol extract, reclaims ethanol, and extractum adds water and makes molten, adds petroleum ether, petroleum ether and solution and extracts repeatedly, merge petroleum ether layer, reclaims petroleum ether and obtain Herba Rosmarini Officinalis ligroin extraction.
Herba Rosmarini Officinalis medical material methanol extraction, merges methanol extract liquid, reclaims methanol, and extractum adds water and makes molten, adds petroleum ether, and petroleum ether and solution according to extraction repeatedly, merge petroleum ether layer, reclaim petroleum ether and obtain Herba Rosmarini Officinalis ligroin extraction.
Herba Rosmarini Officinalis medical material n-butanol extraction, merges n-butanol extracting liquid, reclaims n-butyl alcohol, and extractum adds water and makes molten, adds petroleum ether, and petroleum ether and solution extract repeatedly, merge petroleum ether layer, reclaim petroleum ether and obtain Herba Rosmarini Officinalis ligroin extraction.
8. according to the compositions in claim 1, it is characterized by: be used for treating diabetic nephropathy, the mark of diagnosis diabetic nephropathy is that diabetics urinary albumin excretion ratio persistently raises 20～200 μ g/min, or microdose urine protein is 30～300 μ g/mg with urine creatine ratio.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510942960.4A CN106309546A (en) | 2015-12-17 | 2015-12-17 | Extract for treating diabetic nephropathy |
| PCT/CN2016/074780 WO2016145982A1 (en) | 2015-03-17 | 2016-02-28 | Medical use of carnosic acid |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510942960.4A CN106309546A (en) | 2015-12-17 | 2015-12-17 | Extract for treating diabetic nephropathy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106309546A true CN106309546A (en) | 2017-01-11 |
Family
ID=57726085
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510942960.4A Pending CN106309546A (en) | 2015-03-17 | 2015-12-17 | Extract for treating diabetic nephropathy |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106309546A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109106751A (en) * | 2018-11-01 | 2019-01-01 | 中国药科大学 | A kind of rosemary diterpene extract and the purposes for treating Type I diabetes nephrosis |
| CN112618586A (en) * | 2020-12-29 | 2021-04-09 | 温州医科大学 | Application of extract of total phenolic acid of cauliflower kidney |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2013032316A (en) * | 2011-08-02 | 2013-02-14 | Univ Of Tsukuba | Pharmaceutical composition for controlling progression of renal failure, and pharmaceutical composition for prevention and treatment of complication of renal failure |
| CN104447334A (en) * | 2014-12-22 | 2015-03-25 | 付大亮 | Comprehensive extraction technology of rosmarinic acid, ursolic acid, oleanolic acid and carnosic acid |
| CN105878366A (en) * | 2015-08-27 | 2016-08-24 | 中国药科大学 | Extract capable of reducing blood lipid, reducing blood glucose and protecting liver |
-
2015
- 2015-12-17 CN CN201510942960.4A patent/CN106309546A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2013032316A (en) * | 2011-08-02 | 2013-02-14 | Univ Of Tsukuba | Pharmaceutical composition for controlling progression of renal failure, and pharmaceutical composition for prevention and treatment of complication of renal failure |
| CN104447334A (en) * | 2014-12-22 | 2015-03-25 | 付大亮 | Comprehensive extraction technology of rosmarinic acid, ursolic acid, oleanolic acid and carnosic acid |
| CN105878366A (en) * | 2015-08-27 | 2016-08-24 | 中国药科大学 | Extract capable of reducing blood lipid, reducing blood glucose and protecting liver |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109106751A (en) * | 2018-11-01 | 2019-01-01 | 中国药科大学 | A kind of rosemary diterpene extract and the purposes for treating Type I diabetes nephrosis |
| CN109106751B (en) * | 2018-11-01 | 2021-03-26 | 中国药科大学 | Rosemary diterpene extract and application thereof in treating type I diabetic nephropathy |
| CN112618586A (en) * | 2020-12-29 | 2021-04-09 | 温州医科大学 | Application of extract of total phenolic acid of cauliflower kidney |
| CN112618586B (en) * | 2020-12-29 | 2021-12-28 | 温州医科大学 | Application of extract of total phenolic acid of cauliflower kidney |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103830577B (en) | A kind of medical composition and its use treating hepatobiliary calculus and urinary stone disease | |
| CN101987169A (en) | Composition comprising an extract of herbal combination thereof for preventing and treating diabetes mellitus | |
| CN101111254B (en) | Pharmaceutical composition for treating nephropathy and healthy food comprising herb extracts | |
| CN102240318B (en) | Preparation method and analysis method of traditional Chinese medicine for tonifying qi and increasing breast milk | |
| CN104840777B (en) | A kind of Chinese medicine preparation for treating diabetes and preparation method thereof | |
| CN108567955A (en) | A kind of pharmaceutical composition and preparation method thereof of prevention diabetic nephropathy | |
| CN105209028B (en) | The method for treating Fatty Liver Disease | |
| CN109939153A (en) | A kind of anaesthetic for treating enteritis and preparation method thereof and preparation and preparation method | |
| CN106309546A (en) | Extract for treating diabetic nephropathy | |
| CN101007026A (en) | An anticancer medicinal composition, preparing method and use thereof | |
| CN105412281B (en) | A kind of Chinese medicine composition for treating allergic asthma and preparation method thereof | |
| CN109771457A (en) | Purposes of the russule extract in the preparation that preparation treatment and/or prevention high fat diet cause hepatic injury related disease | |
| CN100493522C (en) | Medicinal composition of oxymatrine and polysaccharide | |
| CN106692789A (en) | Traditional Chinese medicinal composition for preventing and/or treating diabetes and preparation method thereof | |
| CN108175801B (en) | Traditional Chinese medicine composition with chemical liver injury health care function and preparation method thereof | |
| CN102240328B (en) | Traditional Chinese medicine for treating cold and preparation method thereof | |
| CN109771454A (en) | Purposes of the birch young pilose antler extract in the preparation that preparation treatment and/or prevention high fat diet cause hepatic injury related disease | |
| CN110448562A (en) | Application of the lupenone in preparation treatment renal damage drug | |
| CN113171424B (en) | Traditional Chinese veterinary medicine preparation for treating liver lipid deposition of dogs and cats and preparation method thereof | |
| CN1977888B (en) | Medicinal composition of baicalin, ganoderma lucidum and salvia miltrorrhiza | |
| CN1298351C (en) | Chinese medicine oral preparaton for treating urinary system infestation and its preparation method | |
| CN1733055A (en) | Fenugreek seed extract and its preparing process and application | |
| CN109966283A (en) | Application of the degreasing cinnamon polyphenol extract in preparation prevention and treatment diabetic nephropathy product | |
| CN104352748A (en) | Traditional Chinese medicine composition for treating diabetic nephropathy and preparation method thereof | |
| KR101508561B1 (en) | Pharmaceutical composition containing extracts of mixed natural herb include avena sativa thereof for preventing and treating of Diabetic Disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170111 |